Atomoxetine  Oral Solution

4 mg/ml (100 ml)

central nervous system


Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children over the age of 6.
Unipharm’s generic Atomoxetine Oral Solution has been manufactured and marketed in Israel since 2021. In recent years, Unipharm’s Atomoxetine Oral Solution has raised interest in several EU countries.

  • ATC4: N06BA
  • Strengths: 4 mg/ml (100 ml)
  • Dosage forms: Tablets & Oral Solution
  • Out-licensing is offered for all international markets*
  • EU Dossier is available for submission
* Product availability is subject to patent restrictions in countries where applicable patents are in effect

related products